The NICE reference case requirement: more pain for what, if any, gain?

Pharmacoeconomics. 2004;22(4):271-3. doi: 10.2165/00019053-200422040-00006.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Delivery of Health Care / economics*
  • Delivery of Health Care / standards
  • Drug Industry / economics*
  • Drug Industry / standards
  • England
  • Quality-Adjusted Life Years
  • Technology Assessment, Biomedical / economics*
  • Wales